131 related articles for article (PubMed ID: 17191946)
1. Rational design and development of radiation-sensitizing histone deacetylase inhibitors.
Jung M; Kozikowski A; Dritschilo A
Chem Biodivers; 2005 Nov; 2(11):1452-61. PubMed ID: 17191946
[TBL] [Abstract][Full Text] [Related]
2. Bmf contributes to histone deacetylase inhibitor-mediated enhancing effects on apoptosis after ionizing radiation.
Zhang Y; Adachi M; Kawamura R; Zou HC; Imai K; Hareyama M; Shinomura Y
Apoptosis; 2006 Aug; 11(8):1349-57. PubMed ID: 16830229
[TBL] [Abstract][Full Text] [Related]
3. Rational development of histone deacetylase inhibitors as anticancer agents: a review.
Acharya MR; Sparreboom A; Venitz J; Figg WD
Mol Pharmacol; 2005 Oct; 68(4):917-32. PubMed ID: 15955865
[TBL] [Abstract][Full Text] [Related]
4. Novel HDAC inhibitors with radiosensitizing properties.
Jung M; Velena A; Chen B; Petukhov PA; Kozikowski AP; Dritschilo A
Radiat Res; 2005 May; 163(5):488-93. PubMed ID: 15850409
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of thiazole-5-hydroxamic acids as novel histone deacetylase inhibitors.
Anandan SK; Ward JS; Brokx RD; Denny T; Bray MR; Patel DV; Xiao XY
Bioorg Med Chem Lett; 2007 Nov; 17(21):5995-9. PubMed ID: 17827005
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors.
Zhang Y; Jung M; Dritschilo A; Jung M
Radiat Res; 2004 Jun; 161(6):667-74. PubMed ID: 15161353
[TBL] [Abstract][Full Text] [Related]
7. Modulation of cellular radiation responses by histone deacetylase inhibitors.
Karagiannis TC; El-Osta A
Oncogene; 2006 Jun; 25(28):3885-93. PubMed ID: 16462761
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitor and demethylating agent chromatin compaction and the radiation response by cancer cells.
Bar-Sela G; Jacobs KM; Gius D
Cancer J; 2007; 13(1):65-9. PubMed ID: 17464248
[TBL] [Abstract][Full Text] [Related]
9. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.
Weichert W; Röske A; Niesporek S; Noske A; Buckendahl AC; Dietel M; Gekeler V; Boehm M; Beckers T; Denkert C
Clin Cancer Res; 2008 Mar; 14(6):1669-77. PubMed ID: 18347167
[TBL] [Abstract][Full Text] [Related]
10. Development of histone deacetylase inhibitors for cancer treatment.
Marchion D; Münster P
Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis.
Chung YL; Lee MY; Pui NN
Carcinogenesis; 2009 Aug; 30(8):1387-97. PubMed ID: 19351790
[TBL] [Abstract][Full Text] [Related]
12. Analysis of checkpoint responses to histone deacetylase inhibitors.
Beamish H; Warrener R; Gabrielli BG
Methods Mol Biol; 2004; 281():245-59. PubMed ID: 15220534
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel small-molecule histone deacetylase inhibitors by medium-throughput screening using a fluorigenic assay.
Wegener D; Hildmann C; Riester D; Schober A; Meyer-Almes FJ; Deubzer HE; Oehme I; Witt O; Lang S; Jaensch M; Makarov V; Lange C; Busse B; Schwienhorst A
Biochem J; 2008 Jul; 413(1):143-50. PubMed ID: 18384290
[TBL] [Abstract][Full Text] [Related]
14. SIRTUIN 1: regulating the regulator.
Zschoernig B; Mahlknecht U
Biochem Biophys Res Commun; 2008 Nov; 376(2):251-5. PubMed ID: 18774777
[TBL] [Abstract][Full Text] [Related]
15. Zinc binding in HDAC inhibitors: a DFT study.
Wang D; Helquist P; Wiest O
J Org Chem; 2007 Jul; 72(14):5446-9. PubMed ID: 17579460
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors--turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases.
Riester D; Hildmann C; Schwienhorst A
Appl Microbiol Biotechnol; 2007 Jun; 75(3):499-514. PubMed ID: 17377788
[TBL] [Abstract][Full Text] [Related]
17. The effects of histone deacetylase inhibitors on the induction of differentiation in chondrosarcoma cells.
Sakimura R; Tanaka K; Yamamoto S; Matsunobu T; Li X; Hanada M; Okada T; Nakamura T; Li Y; Iwamoto Y
Clin Cancer Res; 2007 Jan; 13(1):275-82. PubMed ID: 17200366
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors preferentially augment transient transgene expression in human dermal fibroblasts.
Yasukawa K; Sawamura D; Goto M; Nakamura H; Shimizu H
Br J Dermatol; 2007 Oct; 157(4):662-9. PubMed ID: 17711521
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors: biology and mechanism of action.
Mehnert JM; Kelly WK
Cancer J; 2007; 13(1):23-9. PubMed ID: 17464243
[TBL] [Abstract][Full Text] [Related]
20. A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
Jones P; Altamura S; De Francesco R; Paz OG; Kinzel O; Mesiti G; Monteagudo E; Pescatore G; Rowley M; Verdirame M; Steinkühler C
J Med Chem; 2008 Apr; 51(8):2350-3. PubMed ID: 18370373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
